Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2) which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.